Recurrent Hairy Cell Leukemia: Clinical Trials

4 trials for Recurrent Hairy Cell Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 active not recruiting, 1 recruiting. 4 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14Completed 2, Active not recruiting 1, Recruiting 1
Phase 21Recruiting 1

Follow Recurrent Hairy Cell Leukemia: new trials by email Literature Review of Recurrent Hairy Cell Leukemia trials Research Report on Recurrent Hairy Cell Leukemia

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)842026-05-292026-07-31
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
Acetaminophen, Dexamethasone, Diphenhydramine - Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia
Phase 1CompletedCity of Hope Medical Center132020-11-182026-01-28
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
Lenalidomide, Obinutuzumab, Oral Azacitidine - Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
Phase 1CompletedJoseph Tuscano82020-10-232025-04-24
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Bendamustine Hydrochloride, Cyclophosphamide - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia
Phase 1Active not recruitingCity of Hope Medical Center372014-10-142026-10-26

Narrower conditions

Leukemia, Hairy Cell (4)  ·  Burkitt Lymphoma (2)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (2)  ·  Lymphoma, B-Cell (2)  ·  Lymphoma, B-Cell, Marginal Zone (2)  ·  Lymphoma, Follicular (2)  ·  Lymphoma, Mantle-Cell (2)  ·  Blastic Plasmacytoid Dendritic Cell Neoplasm (1)  ·  Hematologic Neoplasms (1)  ·  Hodgkin Disease (1)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)  ·  Leukemia, Prolymphocytic, B-Cell (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Mastocytosis, Systemic (1)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)

Broader conditions

Hematologic Diseases (4)  ·  Hemic and Lymphatic Diseases (4)  ·  Immune System Diseases (4)  ·  Immunoproliferative Disorders (4)  ·  Leukemia (4)  ·  Lymphatic Diseases (4)  ·  Lymphoproliferative Disorders (4)  ·  Neoplasms (4)  ·  Neoplasms by Histologic Type (4)  ·  Chronic Disease (3)  ·  Disease Attributes (3)  ·  Leukemia, Lymphoid (3)  ·  Lymphoma (3)  ·  Lymphoma, Non-Hodgkin (3)  ·  Pathologic Processes (3)

Interventions

Acetaminophen (1)  ·  Azacitidine (1)  ·  Bendamustine Hydrochloride (1)  ·  Biopsy (1)  ·  CT-P10 (1)  ·  Calcium Dobesilate (1)  ·  Cladribine (1)  ·  Cyclophosphamide (1)  ·  Dexamethasone (1)  ·  Diphenhydramine (1)  ·  Etoposide (1)  ·  Ibuprofen (1)  ·  Lenalidomide (1)  ·  Ranitidine (1)  ·  Rituximab (1)

Sponsors

City of Hope Medical Center (2)  ·  Joseph Tuscano (1)  ·  National Cancer Institute (NCI) (1)

Countries

United States (4)

Top investigators

Ibrahim T Aldoss (1)  ·  Joseph M Tuscano (1)  ·  Seema A Bhat (1)  ·  Tanya Siddiqi (1)

Results publications

PMID 34492703, PMID 35622074

NIH funding

P30CA033572 (2), P30CA093373 (1), UM1CA186712 (1)